This article is part of the Topical Collection on GI Oncology
Gastric cancer remains a prevalent disease worldwide with a poor prognosis. Helicobacter pylori plays a major role in gastric carcinogenesis. H. pylori colonization leads to chronic gastritis, which predisposes to atrophic gastritis, intestinal metaplasia, dysplasia, and eventually gastric cancer. Screening, treatment, and prevention of H. pylori colonization can reduce the incidence of gastric cancer. Other interventions that may yield a similar effect, although of smaller magnitude, include promotion of a healthy lifestyle including dietary measures, non-smoking, low alcohol intake, and sufficient physical activity. This chapter reviews interventions that can lead to a decline in gastric cancer incidence in high and low incidence countries.
Ferlay J, SI, Ervik M, Dikshit R, et al. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. 2012 [cited 2016 January 25]; Available from: http://globocan.iarc.fr.
Naghavi M, Whang H, Lozano R et al. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71.
Ma JL, Zhang L, Brown LM, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst. 2012;104(6):488–92. The authors demonstrate, in this well designed population based study with long follow up, that gastric cancer incidence is reduced by H. pylori eradication and vitamin intake, but not by garlic intake. CrossRefPubMedPubMedCentral
Lee YC, Chen TH, Chiu HM, et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut. 2013;62(5):676–82. The authors demonstrate in this community based study that the mass eradication of H. pylori is a succesfull intervention in the reduction of gastric cancer incidence. The intervention was effective for reducing the incidence of atrophic gastritis, but not for reducing the incidence of intestinal metaplasia. CrossRefPubMed
Ogura K, Hirata Y, Yanai A, et al. The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. J Clin Gastroenterol. 2008;42(3):279–83. PubMed
Ford AC, Forman D, Hunt R, et al. Helicobacter pylori eradication for the prevention of gastric neoplasia. Cochrane Database Syst Rev. 2015;7:CD005583. This Cochrane meta analysis concludes that there is limited, moderate-quality evidence that searching for and eradicating H. pylori reduces the incidence of gastric cancer in healthy asymptomatic infected Asian individuals, the data cannot necessarily be extrapolated to other populations. PubMed
Li WQ, Ma JL, Zhang L, et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. J Natl Cancer Inst. 2014;106(7).
Nakagawa S, Asaka M, Kato M, et al. Helicobacter pylori eradication and metachronous gastric cancer after endoscopic mucosal resection of early gastric cancer. Aliment Pharmacol Ther. 2006;24:214–8. CrossRef
Uemura N, Mukai T, Okamoto S, et al. Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev. 1997;6(8):639–42. PubMed
Maehata Y, Nakamura S, Fujisawa K, et al. Long-term effect of Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc. 2012;75(1):39–46. In this single center retrospective study the authors studied the effect of H. pylori eradication after the endoscopic resection of early gastric cancer. They do not demonstrate a positive effect of eradication on the development of metachronous gastric cancer. CrossRefPubMed
Bae SE, Jung HY, Kang J, et al. Effect of Helicobacter pylori eradication on metachronous recurrence after endoscopic resection of gastric neoplasm. Am J Gastroenterol. 2014;109(1):60–7. The authors demonstrate with this large retrospective study that there is a positive effect of H. pylori eradication on the occurrence of metachronous gastric cancer after endoscopic resection of early gastric cancer. This positive effect was seen in patient with and without precancerous lesions.
Lansdorp-Vogelaar I, Sharp L. Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention. Best Pract Res Clin Gastroenterol. 2013;27(6):933–47. Study on the cost-effectiveness of H. pylori eradication on gastric cancer incidence in high- and low-incidence countries.
Dinis-Ribeiro M, Areia M, de Vries AC, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Virchows Arch. 2012;460(1):19–46. European guideline on the surveillance of precancerous gastric lesions. CrossRefPubMed
Huang YK, Yu JC, Kang WM, et al. Significance of serum pepsinogens as a biomarker for gastric cancer and atrophic gastritis screening: a systematic review and meta-analysis. PLoS One. 2015;10(11):e0142080. The authors of this meta-analysis conclude that there is great potential in the use of serum pepsinogens as serologic screening. Because of considerable heterogeneity in the studies and possible publication bias, no clear conclusions are drawn on the practical use of pepsinogens as general screening method. CrossRefPubMedPubMedCentral
Ichinose M. Screening for gastric cancer in Japan. In: Wu GY, Aziz K. Cancer screening for common malignancies. Totawa: Humana Press; 2001. p. 87–102.
Hamashima C, Ogoshi K, Narisawa R, et al. Impact of endoscopic screening on mortality reduction from gastric cancer. World J Gastroenterol. 2015;21(8):2460–6. The authors demonstrate a risk reduction of 57 % in gastric cancer by performing population based endoscopic screening. The participation rate in the study was low with only 25 %. CrossRefPubMedPubMedCentral
Yoshida T, Kato J, Inoue I, et al. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and Helicobacter pylori antibody titer. Int J Cancer. 2014;134(6):1445–57. Study on the relationship between gastric cancer development and H. pylori status and serum pepsinogens. The study performed in asymptomatic subjects demonstrates that serum levels of pepsinogens and H. pylori antibody titer provide indices of the risk of gastric cancer development. CrossRefPubMed
Kurilovich S, Belkovets A, Reshetnikov O, et al. Stomach-specific biomarkers (GastroPanel) can predict the development of gastric cancer in a Caucasian population: a longitudinal nested case–control study in Siberia. Anticancer Res. 2016;36(1):247–53. PubMed
Yeh JM, Hur C, Ward Z, et al. Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. Gut. 2015.
Nam JH, Choi IJ, Cho SJ, et al. Association of the interval between endoscopies with gastric cancer stage at diagnosis in a region of high prevalence. Cancer. 2012;118(20):4953–60. The authors demonstrate that a significant benefit in gastric cancer stage at diagnosis was observed in all screened subjects compared to the never screened subjects. Endoscopy intervals of 3 years or less show similar benefits, while intervals of 4 or 5 years lead to the diagnosis of more advanced stage gastric cancer. CrossRefPubMed
Buckland G, Travier N, Huerta JM, et al. Healthy lifestyle index and risk of gastric adenocarcinoma in the EPIC cohort study. Int J Cancer. 2015;137(3):598–606. Data from the EPIC cohort study—a large prospective study conducted in 10 European countries on diet, lifestyle, metabolic, and environmental factors on chronic diseases such as gastric cancer. CrossRefPubMed
Gonzalez CA, Lujan-Barroso L, Bueno-de-Mesquita HB, et al. Fruit and vegetable intake and the risk of gastric adenocarcinoma: a reanalysis of the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study after a longer follow-up. Int J Cancer. 2012;131(12):2910–9. Data from the EPIC cohort study—a large prospective study conducted in 10 European countries on diet, lifestyle, metabolic, and environmental factors on chronic diseases such as gastric cancer. CrossRefPubMed
Jeurnink SM, Buchner FL, Bueno-de-Mesquita HB, et al. Variety in vegetable and fruit consumption and the risk of gastric and esophageal cancer in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2012;131(6):E963-73. Data from the EPIC cohort study—a large prospective study conducted in 10 European countries on diet, lifestyle, metabolic, and environmental factors on chronic diseases such as gastric cancer. CrossRefPubMed
Boehm K, Borrelli F, Ernst E, et al. Green tea (Camellia sinensis) for the prevention of cancer. Cochrane Database Syst Rev. 2009;3, CD005004. PubMed
IARC. Tobacco Smoking and Tobacco Smoke. IARC Monographs [Website] [cited 2016 01–11]; Available from: http://monographs.iarc.fr/ENG/Monographs/vol83/.
Singh PP, Singh S. Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis. Ann Oncol. 2013;24(7):1721–30. The authors performed a meta-analysis on the effect of Statins on gastric cancer risk. The study demonstrates a reduction in gastric cancer risk with the use of statins. The number needed to treat to prevent one gastric cancer case is high. CrossRefPubMed
Kim YI, Kim SY, Kim JH, et al. Long-term Low-dose aspirin use reduces gastric cancer incidence: a Nationwide Cohort Study. Cancer Res Treat. 2015. In this retrospective-matched case–control study, the authors conclude that the use of Aspirin 100 mg once a day results in a reduced gastric cancer risk, particularly in subjects using Aspirin for more than 3 years.
Wong BC, Zhang L, Ma JL, et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut. 2012;61(6):812–8. In this randomized controlled trial the effects of H. pylori eradication and COX-2 inhibitor treatment on gastric cancer risk were studied. H. pylori eradication results in a significant reduction, as does COX-2 inhibitors. No additional risk reduction was demonstrated in a combination of H. pylori eradication and COX-2 inhibitor use.
- Gastric Cancer: How Can We Reduce the Incidence of this Disease?
Caroline M. den Hoed
Ernst J. Kuipers
- Springer US
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II